Developer docs
API playgroundTry for free, no card

Search company profiles

Katalyze AI

Full company profile

uuid0004k2n

Namestring
Katalyze AI
Legal namestring
Katalyze AI
Websiteurl
katalyzeai.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Katalyze AI is a San Francisco-based, venture-backed company building an agentic AI operating system for pharmaceutical manufacturing. The platform unifies fragmented production data from MES, LIMS, historian, and quality systems into a single source-grounded record and deploys domain-trained agents to automate deviation investigations, batch release support, raw material quality management, and process optimization. Core products include the Katalyze AI Platform, the Katalyst AI agent, the Digityze AI digital transformation module, and the Raw Materials AI module, supported by Bio-AI models trained on accredited raw material databases and digital twin technology for both raw materials and processes. The company positions every agent output with GxP traceability by anchoring outputs back to original source records, which is a structural requirement for regulated pharma deployments.

The business operates on an enterprise SaaS model with quote-based custom contracts, targeting the 20 largest pharmaceutical companies globally. Go-to-market is consultative and field-driven, with a "Book a Demo" conversion path and content marketing through a knowledge center, podcasts, blog, and newsroom. Katalyze reports adoption by five of the 20 largest pharmaceutical companies and claims documented outcomes including reduction of deviation investigation time from approximately one year and $4-6M in cost to 45 minutes, 2x faster resolution than human analysts, and up to 8% yield uplift through digital twin-driven process optimization.

The company was founded circa 2024 by Reza Farahani (Founder and CEO), appointed Hannes Bretschneider as Chief AI Officer in December 2025 to lead the agentic AI architecture, launched the Katalyst product in January 2026, and closed a $10.5M seed round led by Bonfire Ventures in June 2026. Headcount is in the 11-50 range. The company is private and headquartered in San Francisco, California.

Short descriptiontext

Katalyze AI is a San Francisco-based startup building an agentic AI platform that unifies pharmaceutical manufacturing data and automates deviation investigations and process optimization for large pharma companies under GxP compliance requirements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing AI, GxP compliance software, deviation investigation platform, biomanufacturing digital twin, agentic process automation
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAI
AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHDAAAKAL
Audit, Explainability & Accountability Tooling (traceability, reporting)
NAICS code2 codes
  • Computer Systems Design Services541512
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
Pharmaceutical Manufacturing AI Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Enterprise SaaS Platform
TypeSubscription Recurring
Description

AI-powered platform for pharmaceutical manufacturing with enterprise licensing model, likely subscription-based given the 'Book a Demo' sales motion and enterprise customer focus.

katalyzeai.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Katalyst
Description

AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability. The AI agent helps reduce manual analysis, improve yields, and prevent batch failures.

prnewswire.com
+2 more records
Core offering1 text field

Katalyze AI builds a GxP-compliant agentic AI platform for pharmaceutical manufacturers that unifies data from MES, LIMS, historian, and quality systems and runs domain-trained AI agents to conduct deviation investigations, optimize processes, and analyze raw materials. The platform includes the Katalyst AI agent and modules such as Digityze AI and Raw Materials AI, supported by 40+ pre-built connectors for rapid deployment. It is sold to large pharmaceutical and biomanufacturing enterprises seeking to shorten deviation analyses, improve yields, and automate GxP-traceable decision workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Deviation investigation time reduced from 2 weeks to 45 minutes
+3 more records
Product overview1 text field

Katalyze AI offers a modular platform architecture anchored by the Katalyze AI Platform as the core GxP-compliant system. The platform integrates specialized AI agents including Katalyst for manufacturing intelligence, Digityze AI for digital transformation, and Raw Materials AI for material optimization. The platform features built-in modules for Process Improvement & Monitoring, Deviation Management & Batch Release, Tech Transfer & CMC, Supply Chain, and Traceability. With 40+ built-in connectors, the platform unifies data from MES, LIMS, historian, and quality systems into a single source-grounded record for pharmaceutical manufacturing operations.

Product and service4 records
1Katalyze AI Platform
CategoryCore enterprise SaaS platform
Description

The primary GxP-compliant agent platform for pharmaceutical manufacturing that unifies scattered production data and runs domain-trained AI agents to conduct deviation investigations and power process improvement for large pharma manufacturers.

2Katalyst
CategoryAI agent product
Description

Katalyst is an AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability, reducing manual analysis, improving yields, and preventing batch failures for large pharma manufacturers.

3Digityze AI
CategoryPlatform add-on module
Description

Digityze AI is an AI-powered module within the Katalyze platform focused on digital transformation capabilities for pharmaceutical manufacturing operations, sold to large pharma manufacturers seeking to modernize their production environments.

4Raw Materials AI
CategoryPlatform add-on module
Description

Raw Materials AI is a module within the Katalyze platform that provides insights on raw materials, leveraging Bio-AI models trained on accredited databases to optimize quality and minimize waste for pharmaceutical manufacturers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GxP-grade quality, manufacturing and compliance SaaS for life sciences. Competes in adjacent workflow slots (deviations, batch release, CAPA) that Katalyze's deviation-management agents are designed to augment.

TypeDirect peer
Description

Scientific R&D and process data platform for pharma/biotech, including bioprocess and CMC workflows. Similar go-to-market of selling AI/analytics on top of unified lab and manufacturing data to large pharma.

TypeEmerging player
Description

Synthetic biology and biomanufacturing platform with its own AI-driven process optimization stack (Codebase/Foundry). Comparable as a vertically-specialized AI player in bioprocess and bio-manufacturing, though more upstream/synthetic biology than pharma manufacturing.

TypeBroad incumbent
Description

Enterprise data operating system with a meaningful pharma manufacturing footprint via Foundry/AIP. Competes for the same agentic-AI-on-manufacturing-data wedge but as part of a much broader platform, not a GxP-specialized product.

TypeBroad incumbent
Description

Dominant SaaS provider for life sciences (Veeva Vault Manufacturing, Quality, etc.). Most relevant comparison as a vertically-specialized pharma SaaS incumbent whose data and quality systems are common integration targets for Katalyze.

TypeDirect peer
Description

Cloud-native data platform for pharma R&D and manufacturing that unifies ELN, LIMS and instrument data. Directly comparable as a pharma/biotech data unification + AI layer, though with stronger R&D vs manufacturing tilt.

TypeBroad incumbent
Description

Global pharma services and data/AI platform with significant manufacturing and quality analytics offerings. Relevant incumbent competitor for enterprise pharma AI/data analytics budgets.

TypeDirect peer
Description

Cloud platform for biotech R&D and process development that centralizes experimental and process data. Comparable vertical SaaS play for life sciences with AI features layered on top of a domain data model.

TypeBroad incumbent
Description

Enterprise PLM and life sciences software (BIOVIA) used by pharma for process development, quality and manufacturing. Competes for similar digital-twin and bioprocess optimization use cases inside a much broader 3DEXPERIENCE stack.

TypeBroad incumbent
Description

Major bioprocess equipment and data analytics vendor; comparable as a supplier of digital tools that sit on top of upstream bioprocess data — a related buyer/competitor dynamic for raw-materials and process digital twins.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Katalyze AI

Pharmaceutical Manufacturing AI Softwarekatalyzeai.com

Katalyze AI is a San Francisco-based startup building an agentic AI platform that unifies pharmaceutical manufacturing data and automates deviation investigations and process optimization for large pharma companies under GxP compliance requirements.

What Katalyze AI does

Katalyze AI is a San Francisco-based, venture-backed company building an agentic AI operating system for pharmaceutical manufacturing. The platform unifies fragmented production data from MES, LIMS, historian, and quality systems into a single source-grounded record and deploys domain-trained agents to automate deviation investigations, batch release support, raw material quality management, and process optimization. Core products include the Katalyze AI Platform, the Katalyst AI agent, the Digityze AI digital transformation module, and the Raw Materials AI module, supported by Bio-AI models trained on accredited raw material databases and digital twin technology for both raw materials and processes. The company positions every agent output with GxP traceability by anchoring outputs back to original source records, which is a structural requirement for regulated pharma deployments.

The business operates on an enterprise SaaS model with quote-based custom contracts, targeting the 20 largest pharmaceutical companies globally. Go-to-market is consultative and field-driven, with a "Book a Demo" conversion path and content marketing through a knowledge center, podcasts, blog, and newsroom. Katalyze reports adoption by five of the 20 largest pharmaceutical companies and claims documented outcomes including reduction of deviation investigation time from approximately one year and $4-6M in cost to 45 minutes, 2x faster resolution than human analysts, and up to 8% yield uplift through digital twin-driven process optimization.

The company was founded circa 2024 by Reza Farahani (Founder and CEO), appointed Hannes Bretschneider as Chief AI Officer in December 2025 to lead the agentic AI architecture, launched the Katalyst product in January 2026, and closed a $10.5M seed round led by Bonfire Ventures in June 2026. Headcount is in the 11-50 range. The company is private and headquartered in San Francisco, California.

Katalyze AI firmographics

Firmographics
Name
Katalyze AI
Legal name
Katalyze AI
Website
https://katalyzeai.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Katalyze AI is a San Francisco-based startup building an agentic AI platform that unifies pharmaceutical manufacturing data and automates deviation investigations and process optimization for large pharma companies under GxP compliance requirements.
Ownership category
akta.pro rank

Katalyze AI industry classification

Industry
Product category
Pharmaceutical Manufacturing AI Software
NAICS
Computer Systems Design Services (541512), Computer Systems Design and Related Services (54151)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAI
AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHDAAAKAL
Audit, Explainability & Accountability Tooling (traceability, reporting)

Keywords

  • Pharmaceutical manufacturing AI
  • GxP compliance software
  • Deviation investigation platform
  • Biomanufacturing digital twin
  • Agentic process automation

Where Katalyze AI is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Katalyze AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise SaaS Platform: AI-powered platform for pharmaceutical manufacturing with enterprise licensing model, likely subscription-based given the 'Book a Demo' sales motion and enterprise customer focus.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Katalyze AI product offering

Product offering

Core offering

Katalyze AI builds a GxP-compliant agentic AI platform for pharmaceutical manufacturers that unifies data from MES, LIMS, historian, and quality systems and runs domain-trained AI agents to conduct deviation investigations, optimize processes, and analyze raw materials. The platform includes the Katalyst AI agent and modules such as Digityze AI and Raw Materials AI, supported by 40+ pre-built connectors for rapid deployment. It is sold to large pharmaceutical and biomanufacturing enterprises seeking to shorten deviation analyses, improve yields, and automate GxP-traceable decision workflows.

Product overview

Katalyze AI offers a modular platform architecture anchored by the Katalyze AI Platform as the core GxP-compliant system. The platform integrates specialized AI agents including Katalyst for manufacturing intelligence, Digityze AI for digital transformation, and Raw Materials AI for material optimization. The platform features built-in modules for Process Improvement & Monitoring, Deviation Management & Batch Release, Tech Transfer & CMC, Supply Chain, and Traceability. With 40+ built-in connectors, the platform unifies data from MES, LIMS, historian, and quality systems into a single source-grounded record for pharmaceutical manufacturing operations.

Differentiator

Problem solved

Functional benefit

Brands

  • Katalyst: AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability. The AI agent helps reduce manual analysis, improve yields, and prevent batch failures.
  • Katalyze
  • Katalyze Agents

Products and services

  • Katalyze AI Platform The primary GxP-compliant agent platform for pharmaceutical manufacturing that unifies scattered production data and runs domain-trained AI agents to conduct deviation investigations and power process improvement for large pharma manufacturers.
  • Katalyst Katalyst is an AI agent designed for pharmaceutical manufacturing that integrates with existing production systems to enhance decision-making and operational reliability, reducing manual analysis, improving yields, and preventing batch failures for large pharma manufacturers.
  • Digityze AI Digityze AI is an AI-powered module within the Katalyze platform focused on digital transformation capabilities for pharmaceutical manufacturing operations, sold to large pharma manufacturers seeking to modernize their production environments.
  • Raw Materials AI Raw Materials AI is a module within the Katalyze platform that provides insights on raw materials, leveraging Bio-AI models trained on accredited databases to optimize quality and minimize waste for pharmaceutical manufacturers.

Quantifiable outcome

  • Deviation investigation time reduced from 2 weeks to 45 minutes
  • +3 more outcomes

Companies that use Katalyze AI

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Katalyze AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Katalyze AI partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Katalyze AI competitors and assessment

Company assessment

Direct peers

  • MasterControl: GxP-grade quality, manufacturing and compliance SaaS for life sciences. Competes in adjacent workflow slots (deviations, batch release, CAPA) that Katalyze's deviation-management agents are designed to augment.
  • Dotmatics: Scientific R&D and process data platform for pharma/biotech, including bioprocess and CMC workflows. Similar go-to-market of selling AI/analytics on top of unified lab and manufacturing data to large pharma.
  • TetraScience: Cloud-native data platform for pharma R&D and manufacturing that unifies ELN, LIMS and instrument data. Directly comparable as a pharma/biotech data unification + AI layer, though with stronger R&D vs manufacturing tilt.
  • Benchling: Cloud platform for biotech R&D and process development that centralizes experimental and process data. Comparable vertical SaaS play for life sciences with AI features layered on top of a domain data model.

Emerging players

  • Ginkgo Bioworks: Synthetic biology and biomanufacturing platform with its own AI-driven process optimization stack (Codebase/Foundry). Comparable as a vertically-specialized AI player in bioprocess and bio-manufacturing, though more upstream/synthetic biology than pharma manufacturing.

Broad incumbents

  • Palantir Foundry: Enterprise data operating system with a meaningful pharma manufacturing footprint via Foundry/AIP. Competes for the same agentic-AI-on-manufacturing-data wedge but as part of a much broader platform, not a GxP-specialized product.
  • Veeva Systems: Dominant SaaS provider for life sciences (Veeva Vault Manufacturing, Quality, etc.). Most relevant comparison as a vertically-specialized pharma SaaS incumbent whose data and quality systems are common integration targets for Katalyze.
  • IQVIA: Global pharma services and data/AI platform with significant manufacturing and quality analytics offerings. Relevant incumbent competitor for enterprise pharma AI/data analytics budgets.
  • Dassault Systèmes (BIOVIA): Enterprise PLM and life sciences software (BIOVIA) used by pharma for process development, quality and manufacturing. Competes for similar digital-twin and bioprocess optimization use cases inside a much broader 3DEXPERIENCE stack.
  • Sartorius (BioAnalytical & Bioprocess): Major bioprocess equipment and data analytics vendor; comparable as a supplier of digital tools that sit on top of upstream bioprocess data — a related buyer/competitor dynamic for raw-materials and process digital twins.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Katalyze AI social profiles

Digital presence

Katalyze AI compliance and trust

Trust signal

Compliance1 record

Katalyze AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Katalyze AI leadership team

Management profile

Number of profiles

Profiles2 records

Katalyze AI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Katalyze AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Katalyze AI

What does Katalyze AI do?

Katalyze AI builds a GxP-compliant agentic AI platform for pharmaceutical manufacturers that unifies data from MES, LIMS, historian, and quality systems and runs domain-trained AI agents to conduct deviation investigations, optimize processes, and analyze raw materials. The platform includes the Katalyst AI agent and modules such as Digityze AI and Raw Materials AI, supported by 40+ pre-built connectors for rapid deployment. It is sold to large pharmaceutical and biomanufacturing enterprises seeking to shorten deviation analyses, improve yields, and automate GxP-traceable decision workflows.

Is Katalyze AI a public or private company?

Katalyze AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Katalyze AI founded?

Katalyze AI was founded in 2024. It employs 11 to 50 people.

Where is Katalyze AI based?

Katalyze AI is headquartered in Mountain View, United States, in the North America region.

How does Katalyze AI make money?

One revenue line is on record: enterprise SaaS Platform.

Who are Katalyze AI's main competitors?

Direct peers on record are MasterControl, Dotmatics, TetraScience and Benchling. Ginkgo Bioworks is listed as an emerging player. Broad incumbents are Palantir Foundry, Veeva Systems, IQVIA, Dassault Systèmes (BIOVIA) and Sartorius (BioAnalytical & Bioprocess).

Does Katalyze AI have an API?

No public API is recorded for Katalyze AI.

What industry is Katalyze AI in?

Katalyze AI's product category is Pharmaceutical Manufacturing AI Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAI, AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI). Its NAICS code is 541512 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AI InsiderKatalyze AI Raises $10.5M to Bring Agentic AI Systems to Pharmaceutical ManufacturingKatalyze AI, a San Francisco-based life sciences AI startup, has raised $10.5 million in seed funding led by Bonfire Ventures with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and individual investors. The company is building an agentic operating system for pharmaceutical manufacturing that integrates data from platforms including MES, LIMS, ELN, and SAP to create unified, traceable operational records for compliance under Good Manufacturing Practice standards. The funding comes as pharmaceutical companies face mounting pressure from patent expirations, supply chain constraints, and rising costs associated with bringing new therapies to market.The SaaS NewsKatalyze AI Raises $10.5M SeedKatalyze AI, a San Francisco-based technology company, announced a $10.5 million seed funding round to accelerate development of its agentic operating system for the pharmaceutical industry. The round was led by Bonfire Ventures with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors. The company plans to use the capital to expand its engineering, science, and go-to-market teams, grow its catalog of domain-trained agents, and scale deployments with its existing global pharmaceutical clients.citybizKatalyze AI Emerges with $10.5M to Build Agentic Operating System Already Deployed By Top Pharma CompaniesKatalyze AI announced it has secured $10.5 million in seed funding led by Bonfire Ventures, with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investor Gokul Rajaram, to roll out an agentic operating system built for the life sciences and pharmaceutical manufacturing sector. The platform deploys autonomous AI agents that operate within FDA-compliant GxP boundaries and is already live across 5 of the 20 largest global pharmaceutical companies, having overseen the delivery of 10 million medication doses. In one commercial deployment, an operational analysis that historically required a full year and cost between $4 million and $6 million was completed by Katalyze's AI agents in 45 minutes.AijournKatalyze AI Raises $10.5M Led by Bonfire Ventures Deploy Agentic Operating System for PharmaKatalyze AI has raised a $10.5 million seed round led by Bonfire Ventures, with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors, to build an agentic operating system for pharmaceutical companies that addresses the industry's need for accurate, hallucination-free AI in drug manufacturing. The platform integrates fragmented lab and manufacturing systems into a unified, GxP-compliant data layer, enabling AI agents to make traceable regulatory decisions. The startup has already deployed its platform across five of the top 20 global pharmaceutical companies and helped deliver 10 million medication doses, with one deployment completing an operational analysis in 45 minutes that would historically have taken a year.BetaKitKatalyze AI thinks the future of pharma operations is teams of AI agentsKatalyze AI announced $10.5 million USD ($14.9 million CAD) in seed funding, led by Bonfire Ventures, to expand its agentic operating system for pharmaceutical firms that enables workers to build AI agent teams for engineering, scientific, and manufacturing tasks. The Toronto and San Francisco-based startup, which counts five of the world's 20 largest pharma companies including Sanofi among its clients, plans to grow its 40-person team and scale deployments across major pharma firms. The company aims to cut the typical eight-to-twelve year, two-billion-dollar drug development timeline in half by 2030.TechStartupsKatalyze AI raises $10.5M to bring agentic AI to pharma manufacturing and life sciencesSan Francisco-based startup Katalyze AI has raised $10.5 million in seed funding led by Bonfire Ventures, with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors, to expand its agentic AI operating system for pharmaceutical manufacturing and life sciences. The platform connects production and laboratory data through integrations with MES, LIMS, ELN, historians, and SAP systems, creating traceable operational records for GxP compliance, and is already deployed at five of the world's 20 largest pharmaceutical companies. The company claims one deployment completed an analysis in 45 minutes that would have taken roughly a year and cost $4 million to $6 million using traditional methods.FinSMEsKatalyze AI Raises $10.5M in Seed FundingKatalyze AI, a Mountain View-based provider of an agentic operating system for pharmaceutical companies, raised $10.5M in seed funding led by Bonfire Ventures, with participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors. The company has already deployed its platform across five of the world's 20 largest pharmaceutical companies, enabling the delivery of 10 million medication doses to patients. The funding will be used to expand operations and development efforts.BitlyKatalyze AI raises $10.5M for pharma workflow softwareKatalyze AI, an agentic operating system for pharmaceutical companies, raised a $10.5 million seed round, as disclosed exclusively by CEO Reza Farahani. The funding comes as investors increasingly back companies that automate the management of pharma bottlenecks, driven by patent cliffs forcing faster drug development and manufacturing timelines.WebWireKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical CompaniesKatalyze AI raised $10.5M in seed funding led by Bonfire Ventures to build an agentic operating system for pharmaceutical companies. The platform is already deployed across 5 of the 20 largest global pharma companies, enabling teams to deliver 10 million medication doses with greater speed and visibility. The company plans to expand its team and scale deployments with larger pharma firms.Venture Capital Access OnlineKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical CompaniesKatalyze AI raised $10.5M in seed funding led by Bonfire Ventures. The agentic operating system is deployed across 5 of the 20 largest global pharma companies, enabling teams to deliver 10 million medication doses with greater speed and visibility. The company will use the funds to expand its team and scale deployments.